1. Introduction {#s0005}
===============

The rapid growth of hospital-acquired infections caused by the bacteria strains resistant to the contemporary antibiotics is one of the greatest challenges of modern antibiotic therapy. Multiple drug-resistant microorganisms, mainly from the *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumanii*, *Pseudomonas aeruginosa* strains and the *Enterobacteriaceae* family, are a major threat to patients ([@b0070], [@b0085]). The resistance of bacteria and yeast to antimicrobial agents is also a significant economic issue. Data gathered by physicians and epidemiologists allows to conclude that one of the reasons for drug resistance among bacteria is the excessive and irresponsible use of antibiotic therapy ([@b0025]).

Many scientific centres have been conducting the research on discovering the new compounds that will successfully constrain the growth of pathogenic microorganisms. One of the substance groups studied are derivatives having 2-sulfanylidene-1,3-thiazolidin-4-one core, commonly known as rhodanine ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Structure of 2-sulfanylidene-1,3-thiazolidin-4-one (rhodanine).

Rhodanine derivatives have a broad spectrum of biological activity demonstrating antibacterial, antifungal, antiviral, antiparasitic, antidiabetic, antineoplastic and anti-inflammatory activity ([@b0045]).

There is a hope that rhodanine derivatives having a carboxyalkyl acid fragment at the N-3 position and arylidene substituents enriched with additional electron donating and withdrawing function groups at the C-5 position, could be used as drugs.

Shingate et al. studied the 5-benzylidene derivatives of rhodanine-3-acetic acid and its activity against *Mycobacterium tuberculosis* and *Mycobactierium bovis* ([@b0100]). Several of the compounds investigated showed good activity against both tested bacterial strains.

Ravi and Sundaram examined the antibacterial properties of 5-benzylidene-rhodanine 3-propionic acid ([@b0105]). The compounds they obtained demonstrated moderate properties against Gram-positive and Gram-negative bacteria. Derivatives of rhodanine-3-acetic acid were also used by Lesyk *et al*., who obtained the derivatives of 3-O-acyloleanolic acids, that demonstrated antineoplastic activity against nine types of cancer ([@b0040]).

Antibacterial and antineoplastic activities were also examined for the 5-benzylidene derivatives of rhodanine-3-isopropionic acid ([@b0110]). Tested by them compounds with NO~2~ group in the ortho position of the aromatic ring system exhibited good antibacterial activity against MRSA. The research conducted by [@b0065]) and [@b0075]) teams demonstrated that the antibacterial activity of rhodanine-3-acetic derivatives was higher when there was a hydrophobic arylidene group having additional electron withdrawing substituents at the C-5 position.

Based on the subject matter literature, we decided to continue our research upon antibacterial activity of rhodanine-3-carboxyalkyl acids derivatives with various substituents at the C-5 position. In our previous research ([@b0120]), we synthesized a series of carboxyalkylrhodanine acids derivatives having an acetic, propionic, butyric or hexanoic acid moiety at the N-3 position. The synthesised compounds underwent the Knoevenagel condensation with 4-diethylaminobenzoic, 4-dibutylaminobenzoic and 4-diphenylaminobenzoic aldehydes. We screened the compound series for their antibacterial activity against selected Gram-positive and Gram-negative bacteria strains. The examined derivatives demonstrated good activity against Gram-positive bacteria and low against Gram-negative ones. During our research, we concluded that the number of carbon atoms in the linker between carboxylic group and the N-3 nitrogen atom has little influence on the antibacterial activity of the investigated compounds. Among the examined group, derivatives having a shorter carbon linker at N-3 had better activity against Gram-positive bacteria than those with longer linker between the carboxylic group and the nitrogen atom. It was observed that the antibacterial activity of the investigated compounds depended on the size of the amino group at the 4′ position in the benzylidene substituent.

Based on our results and the corresponding literature references, we decided to synthesise two series of rhodanine-3-acetic and rhodanine-3-propionic acids derivatives. The first one had a benzylidene substituent with electron donating or withdrawing groups in the aromatic ring. The other had a cinnamylidene substituent with analogous groups in the aromatic ring at the C-5 position.

The compounds used for the investigation are presented in [Table 1](#t0005){ref-type="table"}.Table 1Chemical structures of the investigated compounds. (The compounds marked with an asterisk were previously examined by other teams. The scope of research has been described in the further part of the text).![](fx1.gif)![](fx2.gif)nRnR4a\*12-NO~2~12a12-NO~2~4b\*13-NO~2~12b14-NO~2~4c\*14-NO~2~13a22-NO~2~5a\*22-NO~2~13b24-NO~2~5b\*23-NO~2~14a14-N(CH~3~)~2~5c\*24-NO~2~14b14-N(C~2~H~5~)~2~6a\*14-N(CH~3~)~2~15a24-N(CH~3~)~2~6b\*14-N(C~2~H~5~)~2~15b24-N(C~2~H~5~)~2~7a\*24-N(CH~3~)~2~1614-Cl7b\*24-N(C~2~H~5~)~2~1724-Cl8a12-OCH~3~8b13-OCH~3~8c\*14-OCH~3~9a\*22-OCH~3~9b23-OCH~3~9c24-OCH~3~10a12-Cl10b\*13-Cl10c\*14-Cl11a\*22-Cl11b\*23-Cl11c\*24-Cl

2. Experimental part {#s0010}
====================

2.1. Materials and methods {#s0015}
--------------------------

All reagents for the synthesis of rhodanine derivatives were purchased from Sigma-Aldrich and used without subsequent purification.

Melting point (uncorrected) was determined on the Boetius apparatus. The IR spectrum was recorded with Jasco FT IR-670 Plus spectrophotometer in the KBr disk.

Mass spectrometry analysis was made using AmaZon ETD (Bremen, Germany) equipped with standard electrospray ion source and ion trap analyzer. Samples were dissolved in the mixture of methanol and chloroform (1:1, v/v) with addition of 0.1% formic acid (v/v). Usually, concentration of the sample in solution did not exceed 1 nM. Samples were introduced into a mass spectrometer using a syringe pump with a flow rate of 2 μl/min. Basic settings of the mass spectrometer were as follows: scan range 100--700 *m*/*z*, ion polarity: positive, heated capillary temperature: 280 °C, capillary voltage: −4500 V, ion trap was set to accumulate ca. 300 000 ions for a single cycle.

Fragmentation was done after manual ion selection with an isolation window set to 4 Da. Low energy collision induced dissociation (low energy CID) was used as a fragmentation technique with the collision energy of 1 eV. Typically for ion traps, fragment ion cut-off was set to 27% of the nominal *m*/*z* ratio of selected parent ion. Fragmentation spectra were acquired for about 20 s (equal to ca. 20 spectra) and accumulated.

The NMR spectra were obtained in CDCl~3~ on the Bruker Avance III HD spectrometer operating at 400.17 MHz (1H) and 100.62 MHz (13C); the chemical shifts (ppm) were referenced to lock out the signal of the solvent, and *J* was expressed in Hz.

2.2. General procedure of rhodanine-3-alkanoic acids synthesis {#s0020}
--------------------------------------------------------------

The solution of 11.22 g (0.2 mol) potassium hydroxide in 50 cm^3^ of water was added to the suspension of 0.1 mol of the appropriate amino acid (aminoethanoic acid and 3-aminopropanoic acid). The resulting solution was cooled to 5--10 °C and 7.6 g (0.1 mol) carbon disulfide was added. The content of the flask was mixed at 5--10 °C for 6 h. The cooling bath was removed and mixing was continued at room temperature for 24 h.

The solution of 9.45 g (0.1 mol) chloroacetic acid in 50 cm^3^ water was added to the resulting solution. The solution was mixed for 7 h at the temperature below 15 °C. Next, the solution of 60 cm^3^ hydrochloric acid in 100 cm^3^ of water was added to the flask content. The resulting mixture was heated to 90 °C and kept at that temperature for 20 min. After cooling, a sediment was received, which was drained and crystallized from water.

2.3. General procedure of rhodanine-3-alkanoic acids condensation with aldehydes {#s0025}
--------------------------------------------------------------------------------

0.005 mol of appropriate rhodanine-3-alkanoic acid, 5 g molecular sieves 4A, 25 cm^3^ isopropyl alcohol, 0.0055 mol appropriate aldehyde and 2.53 g (0.025 mol) triethylamine were put into a flask. The mixture was heated under a reflux condenser for 5 h in nitrogen. After heating was finished, the solution was filtered hot. The permeate was cooled and 50 cm^3^ of 2 M hydrochloric acid solution was added. The resulting sediment was filtered using Büchner funnel and crystallized from isopropyl alcohol or glacial acetic acid.

**/4a/ 5-(2′-nitrobenzylidene)-rhodanine-3-acetic acid** ([@b0100], [@b0020]), m.p. 194--196 °C, yield 55.1%, log 1/k~w~ 2.340, MS \[M+1\]^+^ 325, IR cm^−1^: 1729.83 C000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000O, 1714.41 CO conj. 1600.63 CC exo., 1333.53 C---N, 1198.54 CS.

**/4b/ 5-(3′-nitrobenzylidene)-rhodanine-3-acetic acid** ([@b0020]), m.p. 260--262 °C, yield 84.7%, log 1/k~w~ 2.391, MS \[M+1\]^+^ 325, IR cm^−1^: 1761.65 CO, 1714.41 CO conj., 1601.59 CC exo. 1327.75 C---N 1195.65 CS.

**/4c/ 5-(4′-nitrobenzylidene)-rhodanine-3-acetic acid** ([@b0100], [@b0020], [@b0115]), m.p. 269--271 °C, yield 64.5%, log 1/k~w~ 2.114, MS \[M+1\]^+^ 325, IR cm^−1^: 1712.48 CO, 1604.48 CC exo., 1325.82 C---N, 1186.97 CS.

**/5a/ 5-(2′-nitrobenzylidene)-rhodanine-3-propionic acid**, m.p. 193--196 °C, yield 59.9%, log 1/k~w~ 2.613, MS \[M+1\]^+^ 339, IR cm^−1^: 1721.16 CO, 1702.84 CO conj., 1603.52 CC exo., 1180.22 CS, ^1^H NMR (400 MHz, DMSO), ppm, 13.55 (br. s, 1H, [H]{.ul}OOC---), 8.23 (d, *J* = 8.20 Hz, 1H, Ar---H), 8.05 (s, 1H, CHC[H]{.ul}---Ar), 7.91 (t, 1H, Ar---H), 7.75 (d, *J* = 9.04 Hz, 1H, Ar---H), 7.23 (d, *J* = 9.04 Hz, 1H, Ar---H), 4.25 (t, 2H, HOOC---CH~2~---C[H]{.ul}~2~---), 2.66 (t, 2H, HOOC---C[H]{.ul}~2~---CH~2~---), ^13^C NMR (101 MHz, DMSO) ppm, 193.35 (S[C]{.ul}---S), 172.19 (HOO[C]{.ul}---), 166.41 (N---[C]{.ul}O), 143.31 (Ar---NO~2~), 135.18 (C[C]{.ul}H---Ar), 131.90 (S---[C]{.ul}CH---), 129.21 (Ar---C), 129.13 (Ar---C), 127.57 (Ar---C), 126.09 (Ar---C), 40.20 (HOOC---CH~2~---[C]{.ul}H~2~---), 31.22 (HOOC---[C]{.ul}H~2~---CH~2~---).

**/5b/ 5-(3′-nitrobenzylidene)-rhodanine-3-propionic acid** ([@b0105]), m.p. 145--147 °C, yield 65.0%, log 1/k~w~ 2.761, MS \[M+1\]^+^ 339, IR cm^−1^: 1714.41 CO, 1604.48 CC exo., 1334.50 C---N, 1163.83 CS.

**/5c/ 5-(4′-nitrobenzylidene)-rhodanine-3-propionic acid** ([@b0105]), m.p. 248--250 °C, yield 81.2%, log 1/k~w~ 2.922, MS \[M+1\]^+^ 339, IR cm^−1^: 1705.73 CO, 1692.23 CO conj., 1606.41 CC exo., 1318.11 C---N, 1175.54 CS.

**/6a/ 5-(4′-N,N-dimethylaminobenzylidene)-rhodanine-3-acetic acid** ([@b0100], [@b0115]), m.p. 276--278 °C, yield 77.4%, log 1/k~w~ 3.511, MS \[M+1\]^+^ 323, IR cm^−1^: 1717.30 CO, 1703.80 CO conj., 1615.09 CC exo., 1321.96 C---N, 1185.04 CS.

**/6b/ 5-(4′-N,N-diethylaminobenzylidene)-rhodanine-3-acetic acid** ([@b0120]), m.p. 239--241 °C, yield 43.5%, log 1/k~w~ 3.402, MS \[M+1\]^+^ 351, IR cm^−1^: 1719.30 CO, 1699.93 CO conj., 1612.21 CC exo., 1322.95 C---N, 1185.10 CS.

**/7a/ 5-(4′-N,N-dimethylaminobenzylidene)-rhodanine-3-propionic acid** ([@b0115]), m.p. 256--257 °C, yield 40.2%, log 1/k~w~ 3.097, MS \[M+1\]^+^ 337, IR cm^−1^: 1714.41 CO, 1698.98 CO conj., 1616.07 CC exo., 1338.36 C---N, 1166.72 CS.

/7b/ 5-(4′-N,N-dimethylaminobenzylidene)-rhodanine-3-propionic acid ([@b0120]), m.p. 201--203 °C, yield 63.5%, log 1/k~w~ 3.921, MS \[M+1\]^+^ 365, IR cm^−1^: 1716.21 CO, 1700.94 CO conj., 1610.27 CC exo., 1331.61 C---N, 1199.51 CS.

**/8a/ 5-(2′-methoxybenzylidene)-rhodanine-3-acetic acid**, m.p. 220--221 °C, yield 76.8%, log 1/k~w~ 2.478, MS \[M+1\]^+^ 310, IR cm^−1^: 1731.76 CO, 1711.51 CO conj., 1590.99 CC exe., 1325.82 C---N, 1195.65 CS, ^1^H NMR (400 MHz, DMSO), ppm, 13.45 (s, 1H, [H]{.ul}OOC---), 7.99 (s, 1H, CC[H]{.ul}---Ar), 7.57--7.11 (m, 4H Ar---H), 4.74 (t, 2H, HOOC---C[H]{.ul}~2~---), 3.93 (s, 3H, ---CH~3~), ^13^C NMR (101 MHz, DMSO) ppm, 194.27 (S[C]{.ul}---S), 167.78 (HOO[C]{.ul}---), 166.95 (N---CO), 158.66 (Ar---OCH~3~), 134.02 ([C]{.ul}H---Ar), 130.86 (S---CCH---), 129.81 (Ar---C) 122.32 (Ar---C), 121.78 (Ar---C), 121.66 (Ar---C), 112.53 (Ar---C), 56.28 (---O---[C]{.ul}H~3~), 45.47 (HOOC---[C]{.ul}H~2~---).

**/8b/ 5-(3′-methoxybenzylidene)-rhodanine-3-acetic acid**, m.p. 193--195 °C, yield 72.5%, log 1/k~w~ 2.391, MS \[M+1\]^+^ 310, IR cm^−1^: 1722.12 CO, 1708.62 CO conj., 1602.56 CC exe., 1328.71 C---N, 1201.43 CS, ^1^H NMR (400 MHz, DMSO), ppm, 13.45 (s, 1H, [H]{.ul}OOC---), 7.89 (s, 1H, CC[H]{.ul}---Ar), 7.50 (t, 1H, Ar---H) 7.25 (m, 2H, Ar---H), 7.13 (d, *J* = 7.95, 1H, Ar---H), 4.23 (t, 2H, HOOC---C[H]{.ul}~2~---), 3.92 (s, 3H, ---CH~3~), ^13^C NMR (101 MHz, DMSO) ppm, 193.72 (S[C]{.ul}---S), 167.72 (HOO[C]{.ul}---), 166.77 (N---CO), 160.25 (Ar---OCH~3~), 134.64 (Ar---C), 134.42 ([C]{.ul}H---Ar), 131.17 (Ar---C), 122.70 (S---CCH---), 118.45 (Ar---C), 117.75 (Ar---C) 116.37 (Ar---C), 55.85 (---O---[C]{.ul}H~3~), 45.51 (HOOC---[C]{.ul}H~2~---).

**/8c/ 5-(4′-methoxybenzylidene)-rhodanine-3-acetic acid** ([@b0100], [@b0040], [@b0115]), m.p. 247--249 °C, yield 79.6%, log 1/k~w~ 2.506, MS \[M+1\]^+^ 310, IR cm^−1^: 1719.23 CO, 1703.30 CO conj., 1588.09 CC exo., 1322.93 C---N, 1173.47 CS.

**/9a/ 5-(2′-methoxybenzylidene)-rhodanine-3-propionic acid**, m.p. 163--165 °C, yield 71.9%, log 1/k~w~ 2.890, MS \[M+1\]^+^ 324, IR cm^−1^: 1711.51 CO, 1702.53 CO conj., 1588.09 CC exo., 1333.53 C---N, 1174.44 CS, ^1^H NMR (400 MHz, DMSO), ppm, 12.50 (s, 1H, [H]{.ul}OOC---), 7.94 (s, 1H, CC[H]{.ul}---Ar), 7.18 (d, *J* = 8.48, 1H, Ar---H), 7.12 (t, 1H, Ar---H), 4.23 (t, 2H, HOOC---CH~2~---C[H]{.ul}~2~---), 3.92 (s, 3H, ---CH~3~), 2.64 (t, 2H, HOOC---C[H]{.ul}~2~---CH~2~---), ^13^C NMR (101 MHz, DMSO) ppm, 194.24 (S[C]{.ul}---S), 172.21 (HOO[C]{.ul}---), 167.05 (N---CO), 158.62 (Ar---OCH~3~), 133.74 (Ar---C), 130.52 (S---CCH---), 128.70 (Ar---C) 122.79 ([C]{.ul}H---Ar), 121.81 (Ar---C), 121.75 (Ar---C), 112.53 (Ar---C), 56.40 (---O---CH~3~), 31.28 (HOOC---CH~2~---[C]{.ul}H~2~---), 21.51 (HOOC---[C]{.ul}H~2~---CH~2~---).

**/9b/ 5-(3′-methoxybenzylidene)-rhodanine-3-propionic acid**, m.p. 148--150 °C, yield 73.7%, log 1/k~w~ 2.810, MS \[M+1\]^+^ 324, IR cm^−1^: 1710.55 CO, 1696.09 CO conj., 1601.59 CC exe., 1335.46 C---N, 1174.44 CS, ^1^H NMR (400 MHz, DMSO), ppm, 12.40 (s, 1H, [H]{.ul}OOC---), 7.82 (s, 1H, CC[H]{.ul}---Ar), 7.49 (t, 1H, Ar---H), 7.23 (t, 2H, Ar---H), 7.13 (d, *J* = 7.00, 1H, Ar---H), 4.24 (t, 2H, HOOC---CH~2~---C[H]{.ul}~2~---), 3.83 (s, 3H, ---OC[H]{.ul}~3~), 2.65 (t, 2H, HOOC---C[H]{.ul}~2~---CH~2~---), ^13^C NMR (101 MHz, DMSO) ppm, 193.77 (S[C]{.ul}---S), 172.46 (HOO[C]{.ul}---), 167.12 (N---CO), 160.23 (Ar---OCH~3~), 134.80 (CCH---Ar), 133.38 (Ar---C), 131.15 (Ar---C), 123.29 (Ar---C), 122.92 (S---CCH---), 117.47 (Ar---C), 116.27 (Ar---C), 55.88 (---O---[C]{.ul}H~3~), 31.25 (HOOC---CH~2~---[C]{.ul}H~2~---),21.52 (HOOC---[C]{.ul}H~2~---CH~2~---).

**/9c/ 5-(4′-methoxybenzylidene)-rhodanine-3-propionic acid** ([@b0105]), m.p. 226--229 °C, yield 58.7%, log 1/k~w~ 2.981, MS \[M+1\]^+^ 324, IR cm^−1^: 1705.73 CO, 1694.16 CO conj., 1588.04 CC exe., 1338.36 C---N, 1169.62 CS.

**/10a/ 5-(2′-chlorobenzylidene)-rhodanine-3-acetic acid** ([@b0115]), m.p. 236--238 °C, yield 52.8%, log 1/k~w~ 3.049, MS \[M+1\]^+^ 315, IR cm^−1^: 1720.09 CO przeg., 1712.48 CO conj., 1594.84 CC exo., 1321.00 C---N, 1203.36 CS.

**/10b/ 5-(3′-chlorobenzylidene)-rhodanine-3-acetic acid** ([@b0115]), m.p. 225--228 °C, yield 83.9%, log 1/k~w~ 3.171, MS \[M+1\]^+^ 315, IR cm^−1^: 1735.62 CO, 1713.44 CO conj., 1602.56 CC exo., 1327.75 C---N, 1193.72 CS.

**/10c/ 5-(4′-chlorobenzylidene)-rhodanine-3-acetic acid** ([@b0100], [@b0115]), m.p. 270--271 °C, yield 78.9%, log 1/k~w~ 3.962, MS \[M+1\]^+^ 315, IR cm^−1^: 1728.87 CO, 1711.51 CO conj., 1599.66 CC exo., 1331.61 C---N, 1185.04 CS.

**/11a/ 5-(2′-chlorobenzylidene)-rhodanine-3-propionic acid** ([@b0105]), m.p. 144--146 °C, yield 87.8%, log 1/k~w~ 3.567, MS \[M+1\]^+^ 329, IR cm^−1^: 1710.55 CO, 1699.94 CO conj., 1599.66 CC exo., 1328.71 C---N, 1176.36 CS.

**/11b/ 5-(3′-chlorobenzylidene)-rhodanine-3-propionic acid** ([@b0105]), m.p. 193--195 °C, yield 80.8%, log 1/k~w~ 3.267, MS \[M+1\]^+^ 329, IR cm^−1^: 1711.51 CO, 1698.98 CO conj., 1604.48 CC exo., 1314.25 C---N, 1172.51 CS.

**/11c/ 5-(4′-log 1/k~w~ 3.472, chlorobenzylidene)-rhodanine-3-propionic acid** ([@b0105]), m.p. 246--248 °C, yield 83.5%, MS \[M+1\]^+^ − 329, IR cm^−1^: 1705.73 CO, 1695.12 CO conj., 1601.59 CC exo., 1338.36 C---N, 1171.54 CS.

**/12a/ 5-(2′-nitrocinnamylidene)-rhodanine-3-acetic acid**, m.p. 241--242 °C, yield 61.9%, log 1/k~w~ 2.974, MS \[M+1\]^+^ 351, IR cm^−1^: 1751.05 CO, 1715.37 CO conj., 1604.48 CC exo., 1579.41 CC---CC, 1341.25 C---N, 1196.51 CS, ^1^H NMR (400 MHz, DMSO), ppm, 13.43 (br. s, 1H, [H]{.ul}OOC---), 8.08 (d, *J* = 7.68 Hz, 1H, C[H]{.ul}---CHCH---Ar), 8.02 (d, *J* = 7.83 Hz, 1H, CH---CHC[H]{.ul}---Ar), 7.78 (t, 1H, Ar---H), 7.68--7.62 (m, 3H, CH---CHC[H]{.ul}---Ar), 7.19 (dd, *J* = 7.57 Hz, *J* = 14.24 Hz, 1H, CH---C[H]{.ul}CH---Ar), 4.72 (s, 2H, HOOC---CH~2~---), ^13^C NMR (101 MHz, DMSO) ppm, 193.42 (S[C]{.ul}---S), 167.36 (HOO[C]{.ul}---), 166.13 (N---CO), 149.74 (Ar---NO~2~), 139.26 (CH---CH[C]{.ul}H---Ar), 133.96 (CH---[C]{.ul}HCH---Ar), 133.65 ([C]{.ul}H---CHCH---Ar), 131.07 (Ar---C), 130.31 (Ar---C) 129.38 (Ar---C) 128.26 (Ar---C), 126.24 (Ar---C), 125.09 (S---CCH---), 45.43 (HOOC---[C]{.ul}H~2~---).

**/12b/ 5-(4′-nitrocinnamylidene)-rhodanine-3-acetic acid**, m.p. 261--263 °C, yield 92%, log 1/k~w~ 2.632, MS \[M+1\]^+^ 351, IR cm^−1^: 1713.44 CO, 1609.31 CC exo., 1595.81 CC---CC, 1327.75 C---N, 1192.76 CS, ^1^H NMR (400 MHz, DMSO), ppm, 13.38 (s, 1H, [H]{.ul}OOC---), 8.24 (d, *J* = 8.80 Hz, 2H, Ar---H), 7.96 (d, *J* = 8.82 Hz, 2H, Ar---H), 7.59 (d, *J* = 11.40 Hz, 1H, CH---CHC[H]{.ul}---Ar), 7.51 (d, *J* = 15.17, 1H, C[H]{.ul}---CHCH---Ar), 7.36 (dd, *J* = 11.45, *J* = 15.11, 1H, CH---C[H]{.ul}CH---Ar), 4.71 (s, 2H, HOOC---C[H]{.ul}~2~---), ^13^C NMR (101 MHz, DMSO) ppm, 193.33 (S[C]{.ul}---S), 167.75 (HOO[C]{.ul}---), 166.16 (N---CO), 147.97 ((Ar---NO~2~), 143.05 (CH---CH[C]{.ul}H---Ar), 142.27 (CH---[C]{.ul}HCH---Ar), 133.53 ([C]{.ul}H---CHCH---Ar), 129.51 (Ar---C), 128.10 (Ar---C), 126.39 (Ar---C), 124.51 (S---CCH---), 45.41 (HOOC---C[H]{.ul}~2~---).

**/13a/ 5-(2′-nitrocinnamylidene)-rhodanine-3-propionic acid**, m.p. 198--201 °C, yield 58.6%, log 1/k~w~ 3.269, MS \[M+1\]^+^ 365, IR cm^−1^: 1724.05 CO, 1707.66 CO conj., 1606.41 CC exo., 1583.27 CC---CC, 1344.14 C---N, 1176.36 CS, ^1^H NMR (400 MHz, DMSO), ppm, 13.38 (s, 1H, [H]{.ul}OOC---), 8.15 (d, *J* = 7.82, 1H, CH---CHC[H]{.ul}---Ar), 7.72 (t, 1H, Ar---H), 7.70--7.65 (m, 3H, Ar---H), 7.32 (dd, *J* = 7.58, *J* = 14.86, 1H, CH---C[H]{.ul}CH---Ar), 4.35 (t, 2H, HOOC---CH~2~---C[H]{.ul}~2~---), 2.70 (t, 2H, HOOC---C[H]{.ul}~2~---CH~2~---), ^13^C NMR (101 MHz, DMSO) ppm, 192.54 (S[C]{.ul}---S), 171.30 (HOO[C]{.ul}---), 166.38 (N---CO), 151.20 ((Ar---NO~2~), 136.15 (CH---CH[C]{.ul}H---Ar), 135.21 (CH---[C]{.ul}HCH---Ar), 132.55 ([C]{.ul}H---CHCH---Ar), 131.10 (Ar---C), 129.55 (Ar---C), 128.70 (S---CCH---), 128.17 (Ar---C), 127.62 (Ar---C), 125.25 (Ar---C), 43.38 (HOOC---CH~2~---CH~2~---), 32.25 (HOOC---CH~2~---CH~2~---).

**/13b/ 5-(4′-nitrocinnamylidene)-rhodanine-3-propionic acid**, m.p. 244--245 °C, yield 56.3%, log 1/k~w~ 3.742, MS \[M+1\]^+^ 365, IR cm^−1^: 1703.80 CO, 1698.06 CO conj., 1596.77 CC---CC, 1320.10 C---N, 1159.97 CS, ^1^H NMR (400 MHz, DMSO), ppm, 12.50 (br. s, 1H, [H]{.ul}OOC---), 8.26 (d, *J* = 8.85 Hz, 2H, Ar---H), 7.96 (d, *J* = 8.84 Hz, 2H, Ar---H), 7.55(d, *J* = 11.41 Hz 1H, CH---CHC[H]{.ul}---Ar), 7.52 (d, *J* = 15.09 Hz, 1H, C[H]{.ul}---CHCH---Ar), 7.37 (dd, *J* = 11.49 Hz, *J* = 15.06 Hz, 1H, CH---C[H]{.ul}CH---Ar), 4.21 (t, 2H, HOOC---CH~2~---C[H]{.ul}~2~---), 2.62 (t, 2H, HOOC---C[H]{.ul}~2~---CH~2~---), ^13^C NMR (101 MHz, DMSO) ppm, 193.44 (S[C]{.ul}---S), 172.20 (HOO[C]{.ul}---), 166.54 (N---CO), 147.94 ((Ar---NO~2~), 142.46 (CH---CH[C]{.ul}H---Ar), 142.39 (CH---[C]{.ul}HCH---Ar), 132.56 ([C]{.ul}H---CHCH---Ar), 129.45 (Ar---C), 128.24 (S---CCH---), 127.14 (Ar---C), 124.55 (Ar---C), 40.95 (HOOC---CH~2~---[C]{.ul}H~2~---), 31.25 (HOOC---[C]{.ul}H~2~---CH~2~---).

**/14a/ 5-(4′-N,N-dimethylaminocinnamylidene)-rhodanine-3-acetic acid**, m.p. 273--274 °C, yield 44.0%, log 1/k~w~ 3.398, MS \[M+1\]^+^ 349, IR cm^−1^: 1736.58 CO, 1697.05 CO conj., 1609.62 CC exo., 1563.99 CC---CC, 1321.90 C---N, 1160.94 CS, ^1^H NMR (400 MHz, DMSO), ppm, 13.35 (br.s, 1H, [H]{.ul}OOC---), 7.59--7.56 (m, 3H, CH---CHC[H]{.ul}---Ar), 7.34 (d, *J* = 14.76 Hz, 1H, C[H]{.ul}---CHCH---Ar), 6.83 (dd, *J* = 11.81 Hz, *J* = 14.79 Hz, 1H, CH---C[H]{.ul}CH---Ar), 6.74 (d, *J* = 8.93 Hz, 2H, Ar---H), 4.69 (s, 2H, HOOC---C[H]{.ul}~2~---),), 3.02 (s, 6H, -N(C[H]{.ul}~3~)~2~, ^13^C NMR (101 MHz, DMSO) ppm, 192.85 (S[C]{.ul}---S), 167.94 (HOO[C]{.ul}---), 166.03 (N---CO), 152.34 (Ar---N(CH~3~)~2~), 148.60 (CH---CH[C]{.ul}H---Ar), 136.73 (Ar---C), 130.93 (Ar---C), 123.49 (CH---[C]{.ul}HCH---Ar), 118.62 ([C]{.ul}H---CHCH---Ar), 118.50 (S---CCH---), 112.35 (Ar---C), 45.32 (HOOC---[C]{.ul}H~2~---N), 40.17 (-N([C]{.ul}H~3~)~2~).

**/14b/ 5-(4′-N,N-diethylaminocinnamylidene)-rhodanine-3-acetic acid**, m.p. 263--265 °C, yield 51.2%, log 1/k~w~ 4.152, MS \[M+1\]^+^ 377, IR cm^−1^: 1713.44 CO, 1693.19 CO conj., 1611.23 CC exo., 1588.09 CC---CC, 1322.93 C---N, 1195.65 CS, ^1^H NMR (400 MHz, DMSO), ppm, 13.39 (s, 1H, [H]{.ul}OOC---), 7.62--7.49 (m, 3H, CH---CHC[H]{.ul}---Ar), 7.34 (d, *J* = 14.76 Hz, 1H, C[H]{.ul}---CHCH---Ar), 6.78 (dd, *J* = 11.89 Hz, *J* = 14.58 Hz, 1H, CH---C[H]{.ul}CH---Ar), 6.70 (d, *J* = 8.80 Hz, 2H, Ar---H), 4.68 (s, 2H, HOOC---CH~2~---), 3.42 (q, 4H, ---N(C[H]{.ul}~2~CH~3~)~2~, 1.12 (t, 6H, ---N(CH~2~C[H]{.ul}~3~)~2~), ^13^C NMR (101 MHz, DMSO) ppm, 192.72 (S[C]{.ul}---S), 167.94 (HOO[C]{.ul}---), 165.93 (N---CO), 149.96 (Ar---C), 148.70 (CH---CH[C]{.ul}H---Ar), 136.87 (CH---[C]{.ul}HCH---Ar), 131.34 (Ar---C), 122.80 ([C]{.ul}H---CHCH---Ar), 118.07 (S---CCH---), 117.95 (Ar---C), 111.82 (Ar---C), 45.31 (---N([C]{.ul}H~2~CH~3~)~2~), 44.36 (HOOC---[C]{.ul}H~2~---N), 12.96 (---N(CH~2~[C]{.ul}H~3~)~2~).

**/15a/ 5-(4′-N,N-dimethylaminocinnamylidene)-rhodanine-3-propionic acid**, m.p. 244--245 °C, yield 46.4%, log 1/k~w~ 3.711, MS \[M+1\]^+^ 363, IR cm^−1^: 1734.66 CO, 1697.05 CO conj., 1612.20 CC exo., 1593.88 CC---CC, 1326.79 C---N, 1159.97 CS, ^1^H NMR (400 MHz, DMSO), ppm, 12.49 (br.s, 1H, [H]{.ul}OOC---), 7.55 (d, *J* = 8.93 Hz, 2H, Ar---H), 7.50 (d, *J* = 11.61, 1H, CH---CHC[H]{.ul}---Ar), 6.78 (dd, *J* = 11.81 Hz, *J* = 14.88 Hz, 1H, CH---C[H]{.ul}CH---Ar), 7.34 (d, *J* = 14.76 Hz, 1H, C[H]{.ul}---CHCH---Ar), 4.19 (t, 2H, HOOC---CH~2~---C[H]{.ul}~2~---), 3.03 (s, 6H, ---N(C[H]{.ul}~3~)~2~, 2.60 (t, 2H, HOOC---C[H]{.ul}~2~---CH~2~---), ^13^C NMR (101 MHz, DMSO) ppm, 192.76 (S[C]{.ul}---S), 172.23 (HOO[C]{.ul}---), 166.35 (N---CO), 152.24 (Ar---N(CH~3~)~2~), 147.56 (CH---CH[C]{.ul}H---Ar), 130.77 (Ar---C), 129.15 (Ar---C), 123.54 (CH---[C]{.ul}HCH---Ar), 119.14 ([C]{.ul}H---CHCH---Ar), 118.69 (S---CCH---), 112.34 (Ar---C), 40.15 (HOOC---CH~2~---[C]{.ul}H~2~---N), 39.79 (---N([C]{.ul}H~3~)~2~), 31.35 (HOOC---[C]{.ul}H~2~---CH~2~---N).

**/15b/ 5-(4′-N,N-diethylaminocinnamylidene)-rhodanine-3-propionic acid**, m.p. 242--245 °C, yield 56.1%, log 1/k~w~ 4.551, MS \[M+1\]^+^ 391, IR cm^−1^: 1713.44 CO, 1703.80 CO conj., 1611.20 CC exo., 1563.02 CC---CC, 1324.75 C---N, 1193.72 CS, ^1^H NMR (400 MHz, DMSO), ppm, 12.49 (br.s, 1H, [H]{.ul}OOC---), 7.54--7.74 (m, 3H, CH---CHC[H]{.ul}---Ar), 7.29 (d, *J* = 14.76 Hz, 1H, C[H]{.ul}---CHCH---Ar), 6.78 (s, 1H, CH---C[H]{.ul}CH---Ar), 6.75 (d, *J* = *2*.96 Hz, 2H, Ar---H), 4.19 (t, 2H, HOOC---CH~2~---C[H]{.ul}~2~---),), 3.42 (q, 4H, ---N(C[H]{.ul}~2~CH~3~)~2~, 1.12 (t, 6H, ---N(CH~2~C[H]{.ul}~3~)~2~, ^13^C NMR (101 MHz, DMSO) ppm, 192.67 (S[C]{.ul}---S), 172.23 (HOO[C]{.ul}---), 166.33 (N---CO), 149.85 (Ar---C), 148.10 (CH---CH[C]{.ul}H---Ar), 136.12 (CH---[C]{.ul}HCH---Ar), 131.19 (Ar---C), 120.85 ([C]{.ul}H---CHCH---Ar), 118.61 (Ar---C), 118.16 (S---CCH---), 111.84 (Ar---C), 111.82 (Ar---C), 44.34 (---N([C]{.ul}H~2~CH~3~)~2~), 40.35 (HOOC---CH~2~---[C]{.ul}H~2~---N), 31.36 (HOOC---[C]{.ul}H~2~---CH~2~---N), 12.96 (---N(CH~2~[C]{.ul}H~3~)~2~).

**/16/ 5-(4′-chlorocinnamylidene)-rhodanine-3-acetic acid**, m.p. 262--265 °C, yield 63.0%, log 1/k~w~ 3.984, MS \[M+1\]^+^ 341, IR cm^−1^: 1715.37 CO, 1703.80 CO conj., 1604.48 CC exo., 1572.65 CC---CC, 1331.61 C---N, 1165.76 CS, ^1^H NMR (400 MHz, DMSO), ppm, 13.45 (s, 1H, [H]{.ul}OOC---), 7.59 (d, *J* = 8.32 Hz, 2H, Ar---H), 7.50 (d, *J* = 11.44 Hz, 1H, C[H]{.ul}---CHCH---Ar), 7.43 (t, 3H, CH---CHC[H]{.ul}---Ar), 7.18 (dd, *J* = 11.69 Hz, *J* = 14.89 Hz, 1H, CH---C[H]{.ul}CH---Ar), 4.70 (s, 2H, HOOC---C[H]{.ul}~2~---), ^13^C NMR (101 MHz, DMSO) ppm, 193.39 (S[C]{.ul}---S), 167.80 (HOO[C]{.ul}---), 166.18 (N---CO), 144.79 (CH---CH[C]{.ul}H---Ar), 135.12 ((Ar---Cl), 134.89 (Ar---C), 134.46 (CH---[C]{.ul}HCH---Ar), 130.34 (Ar---C), a29.51 (Ar---C), 124.92 ([C]{.ul}H---CHCH---Ar), 124.17 (S---CCH---), 45.42 (HOOC---[C]{.ul}H~2~---).

**/17/ 5-(4′-chlorocinnamylidene)-rhodanine-3-propionic acid**, m.p. 258--261 °C, yield 72.3%, log 1/k~w~ 4.501, MS \[M+1\]^+^ 355, IR cm^−1^: 1715.37 CO, 1701.87 CO conj., 1603.52 CC exo., 1590.77 CC---CC, 1334.50 C---N, 1159.97 CS, ^1^H NMR (400 MHz, DMSO), ppm, 12.50 (s, 1H, [H]{.ul}OOC---), 7.74 (d, *J* = 8.55 Hz, 2H, Ar---H), 7.50 (t, 3H, CH---CHC[H]{.ul}---Ar), 7.39 (d, *J* = 15.17 Hz, 1H, C[H]{.ul}---CHCH---Ar), 7.14 (dd, *J* = 11.53 Hz, *J* = 15.12 Hz, 1H, CH---C[H]{.ul}CH---Ar), 4.20 (t, 2H, HOOC---CH~2~---C[H]{.ul}~2~---), 2.62 (t, 2H, HOOC---C[H]{.ul}~2~---CH~2~---), ^13^C NMR (101 MHz, DMSO) ppm, 193.40 (S[C]{.ul}---S), 172.21 (HOO[C]{.ul}---), 166.51 (N---CO), 144.17 (CH---CH[C]{.ul}H---Ar), 134.97 ((Ar---Cl), 134.94 (CH---[C]{.ul}HCH---Ar), 130.25 (Ar---C), 124.86 ([C]{.ul}H---CHCH---Ar), 124.81 (S---CCH---), 121.78 (Ar---C), 40.91 (HOOC---CH~2~---[C]{.ul}H~2~---), 31.27 (HOOC---[C]{.ul}H~2~---CH~2~---).

2.4. Antibacterial activity *in vitro* assay {#s0030}
--------------------------------------------

All target compounds were screened for antibacterial and antifungal activities by micro-dilution broth method using Mueller-Hinton broth and Mueller-Hinton broth with 5% lysed sheep blood for growth of non-fastidious and fastidious bacteria, respectively, or Mueller-Hinton broth with 2% glucose for growth of fungi. Minimal inhibitory concentration (MIC) of tested compounds were evaluated for the panel of reference microorganism from American Type Culture Collection (ATCC), including Gram-negative bacteria (*S. typhimurium ATCC 14028, E. coli ATCC 25922, P. mirabilis ATCC 12453, K. pneumoniae ATCC 13883, P. aeruginosa ATCC 9027*), Gram-positive bacteria (*S. aureus ATCC 25923, S. aureus ATCC 6538, S. aureus ATCC 43300, S. epidermidis ATCC 12228, M. luteus ATCC 10240, B. subtilis ATCC 6633, B. cereus ATCC 10876, S. pyogenes ATCC 19615, S. pneumoniae ATCC 49619, S. mutans ATCC 25175*) and fungi (*C. albicans ATCC 102231, C. albicans ATCC 2091, C. parapsilosis ATCC 22019, C. glabrata ATCC 90030, C. krusei ATCC 14243*). A detailed procedure for the determination of MIC value was presented in earlier publication ([@b0120]).

2.5. Measurement of lipophilicity {#s0035}
---------------------------------

The chromatographic measurements were carried out using Shimadzu LC-20A liquid chromatographic system and a computer software LC Solution Version 1.24 to control the hardware and store the chromatographic data. Measurements were performed applying a column packed with Eurospher II 100-3-C18A (Knauer; 12.5 cm × 4 mm i.d.) using methanol-water mixtures as mobile phases. Volume fraction of the organic modifier varied from 0.9 to 0.4 with increment 0.1. The mobile phase flow-rate was 1 mL min^−1^. All measurements were made at 20 °C. The test compounds were separately dissolved (10^−3^ mg mL^−1^) in the organic modifier and detected using UV--VIS detector. For calculations, average values of the retention factors from at least three experimental replicates were taken. The dead time was evaluated from uracil peak.

The descriptor of lipophilicity or hydrophobicity (log *k*~w~ value) was determined on the basis of a series of isocratic measurements at different concentrations of the organic modifier (methanol) in a two-component mobile phase and linear extrapolation of the relationship between log *k* and the volume fraction (*φ*) of the methanol to its zero content (to 100% of water). The log *k~w~* values determined by the extrapolation methods depended to a high degree on the range of the organic modifier concentrations, at which measurements and then extrapolation were made ([@b0055]). In this case, the concentration range (*φ*) from 0.4 to 0.9 was used for all examined substances.

2.6. X-ray analysis {#s0040}
-------------------

Crystals suitable for an X-ray structure analysis were obtained from a mixture of ethanol and dimethylformamide for **15b** and from a mixture of methanol and dimethyl sulfoxide for **17**, by slow evaporation of the solvent at room temperature.

Data for single crystals of **15b** and **17** were collected using the Oxford Diffraction SuperNova four circle diffractometer equipped with the Mo (0.71073 Å) Kα for **15b** and Cu (1.54184 Å) Kα for **17** radiation source and graphite monochromator. The phase problems were solved by direct methods using SIR-2014 program ([@b0005]) and all non-hydrogen atoms were refined anisotropically using weighted full-matrix least-squares on F^2^. Refinement and further calculations were carried out using SHELXL program ([@b0090]). The hydrogen atoms bonded to carbons were included in the structure at idealized positions and were treated using a riding model with U~iso~(H) fixed at 1.2 U~eq~ of C and 1.5 U~eq~ for methyl groups. Hydrogen atoms attached to oxygen atoms were found from the difference Fourier map and refined without any restraints. For molecular graphics, MERCURY ([@b0060]) software was used.

**15b**: C~19~H~22~N~2~O~3~S~2~, M~r~ = 390.50, crystal size = 0.11 × 0.22 × 0.59 mm^3^, triclinic, space group *P*$\overline{1}$, a = 8.3065(4) Å, b = 11.5949(6) Å, c = 12.2345(6) Å, α = 112.675(5)°, β = 98.541(4)°, γ = 108.445(4)°, V = 980.92(9) Å^3^, Z = 2, T = 130(2) K, 13,135 reflections collected, 4605 unique reflections (R~int~ = 0.0280), R1 = 0.0464, wR2 = 0.1138 \[I \> 2σ(I)\] and R1 = 0.0659, wR2 = 0.1265 \[all data\].

**17**: C~15~H~12~ClNO~3~S~2~·C~2~H~6~OS, M~r~ = 431.95, crystal size = 0.04 × 0.16 × 1.00 mm^3^, monoclinic, space group *C*2/*c*, a = 41.440(1) Å, b = 4.8420(2) Å, c = 20.0207(5) Å, β = 97.650(3)°, V = 3981.4(2) Å^3^, Z = 8, T = 130(2) K, 28,073 reflections collected, 3848 unique reflections (R~int~ = 0.0490), R1 = 0.0384, wR2 = 0.1020 \[I \> 2σ(I)\] and R1 = 0.0416, wR2 = 0.1052 \[all data\].

CCDC 1877705 and 1877706 contain the supplementary crystallographic data, for **15b** and **17**, respectively. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre *via* [www.ccdc.cam.ac.uk/data_request/cif](http://www.ccdc.cam.ac.uk/data_request/cif){#ir005}.

3. Results and discussion {#s0045}
=========================

3.1. Chemical synthesis {#s0050}
-----------------------

The synthesis of rhodanine-3-acetic and rhodanine-3-propionic acids was conducted according to the modified procedure proposed by Körner at the beginning of the 20th century ([@b0050]) ([Scheme 1](#f0040){ref-type="fig"}).Scheme 13-Carboxyalkylrhodanine acids synthesis.

The Knoevenagel condensation of the obtained rhodanine-3-carboxyalkyl acids with benzaldehyde and cinnamaldehyde derivatives was conducted according to the procedure proposed for the analogues of 2-\[(5*Z*)-5-\[(*E*)-2-methyl-3-phenylprop-2-enylidene\]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl\]acetic acid commonly referred to as epalrestat ([@b0135]) ([Scheme 2](#f0045){ref-type="fig"} and [Scheme 3](#f0050){ref-type="fig"}).Scheme 23-Carboxyalkylrhodanine acids condensation with benzaldehyde derivatives.Scheme 33-Carboxyalkylrhodanine acids condensation with cinnamaldehyde derivatives.

3.2. Antimicrobial activity {#s0055}
---------------------------

The 3-carboxyalkylrhodanine acids derivatives having a cinnamaldehyde fragment at the C-5 position are rarely discussed in the literature on the subject. The best known example of such compound is epalrestat, 2-\[(5*Z*)-5-\[(*E*)-2-methyl-3-phenylprop-2-enylidene\]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl\]acetic acid, that is an aldose reductase inhibitor used for the treatment of diabetic neuropathy ([@b0035]).

In our current research, we decided to compare the antibacterial activity of rhodanine-3-acetic and rhodanine-3-propionic acids having benzylidene and cinnamylidene groups with additional electron donating or withdrawing groups at the C-5 position. None of the tested compounds influenced effectively against Gram-negative bacteria and yeast (MIC \> 1000 mg/L, data not shown in main text. All measured MIC and MBC values are given in the Supplement Materials. Tables S1--S3). Minimal inhibitory concentration (MIC) values of the derivatives against Gram-positive bacteria are included in [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}.Table 2Biological activity of derivatives containing a nitro or amino group in the benzylidene substituent.CompoundMicroorganism**4a4b4c5a5b5c6a6b7a7b**MIC (mg/L)*S. aureus* ATCC 2592312525012515.6250\>100050025050031.25*S. aureus* ATCC 6538250250250125125\>100050012525031.25*S. aureus* ATCC 43300250250250125125\>100050012525031.25*S. epidermidis* ATCC 1222812550031,331.3250\>1000\>100025050031.25*M. luteus* ATCC 102402501000125125500\>100025062.5100062.5*B. subtilis* ATCC 663362.550025015.662.5\>100025062.550015.6*B. cereus* ATCC 10876250250250125250\>1000\>100012525031.25*S. pyogenes* ATCC 19615125\>100012562.5\>1000\>100025012525062.5*S. pneumoniae* ATCC 49619250\>1000125250\>1000\>100012562.525062.5*S. mutans* ATCC 25175250\>1000250500\>1000\>10001000250500250Table 3Biological activity of derivatives containing a methoxy or chloro group in the benzylidene substituent.MicroorganismCompound**8a8b8c9a9b9c10a10b10c11a11b11c**MIC (mg/L)*S. aureus* ATCC 2592310001000500125\>1000\>1000250\>100050062.5250125*S. aureus* ATCC 65385005001000125\>1000\>1000250\>1000100031.25250125*S. aureus* ATCC 43300500500100062.5\>1000\>1000250\>100050031.25250125*S. epidermidis* ATCC 122281000100010001000\>1000500250\>100050031.25500125*M. luteus* ATCC 102402502502501000\>1000\>1000250\>100025062.51000500*B. subtilis* ATCC 66335001000500250\>1000\>1000250\>100050062.5250125*B. cereus* ATCC 108761000100010001000\>10001000500\>100050062.5250125*S. pyogenes* ATCC 196151000500\>1000250\>1000\>1000250\>100050062.510001000*S. pneumoniae* ATCC 49619500\>1000\>1000125\>1000\>1000500\>100050062.510001000*S. mutans* ATCC 251751000\>1000\>10001000\>1000\>1000500\>10001000500\>10001000Table 4Biological activity of derivatives containing a nitro, amino, methoxy or chloro group in the cinnamylidene substituent.MicroorganismCompound**12a12b13a13b14a14b15a15b1617**MIC (mg/L)*S. aureus* ATCC 2592325015.615.67.8100012562.531.25500125*S. aureus* ATCC 653850025012562.550012515.631.25250125*S. aureus* ATCC 4330050015.662.57.850062.562.531.25250125*S. epidermidis* ATCC 1222810003.931.251.9850062.531.2531.251000125*M. luteus* ATCC 1024025025050031.2525062.512531.25500125*B. subtilis* ATCC 6633500100062.53.950062.515.631.2525062.5*B. cereus* ATCC 10876500\>100012562.550012515.631.25125125*S. pyogenes* ATCC 1961550031.2512562.5\>100012562.5125500\>1000*S. pneumoniae* ATCC 4961912512562.562.550012531.2562.5250\>1000*S. mutans* ATCC 251751000\>10001000500\>10001252501251000\>1000

Some compounds tested by our team have been obtained and tested by other researchers and by us. We have previously studied the antimicrobial activity of compounds 6b and 7b \[12\]. In this work, both compounds were used to compare the influence of molecular structure on biological activity.

Derivatives **4a**, **4b** and **4c** were examined by Talele et al. They were reported their anti MRSA activity ([@b0020]). Derivatives: **5a**, **5b**, **5c**, **9a**, **11a**, **11b** and **11c** were examined by Sundaram and Ravi. They determined their influence on two Gram-positive bacteria strains (*Staphylococcus aureus, Bacillus cereus*) and one Gram-negative bacterium strain (*Escherichia coli*). The activity of the compounds examined was described as moderate ([@b0105]).

Derivative **7a** was used by the Lesyk team to synthesize more complex systems demonstrating antineoplastic activity ([@b0040]).

Derivatives **4c**, **6a** and **10c** examined towards their activity against tuberculosis by the Shingate team ([@b0100]) were described in patent literature by Tanouchi, who reported them as potential aldose reductase inhibitors ([@b0115]).

Compound **8c** was described by three research teams mentioned above ([@b0100], [@b0040], [@b0115]). The derivative **10b** was previously described as a potential aldose reductase inhibitor ([@b0115]).

None of the 3-carboxyalkylrhodanine acids derivatives tested in our study demonstrated activity against Gram-negative bacteria and yeast (MIC \> 1000 mg/L), similarly to the compounds described in our previous publication ([@b0120]). The conclusion was contrary to our anticipations, since we expected that the derivatives having a cinnamylidene substituent at the C-5 position would demonstrate at least moderate activity in suppressing the growth of this type of microorganisms.

The derivatives of rhodanine-3-propionic acid with p-N,N-diethylcinnamylidene and p-N,N-diethylbenzylidene substituents at the C-5 position demonstrated the highest activity against Gram-positive bacteria. Derivative **15b** inhibited the growth of Gram-positive bacteria at the concentration of 31.25 mg/L, whereas compound **7b** inhibited the growth of Gram-positive bacteria at the concentration between 15.6 and 250 mg/L. We consider that the presence of the N,N-diethylamine group in the aromatic system and the number of carbon atoms in the carboxyalkyl group is more significant for the biological activity than the fact that the benzylidene or cinnamylidene substituent was present at the C-5 position.

The compounds with the benzylidene substituent containing electron withdrawing NO~2~ group from the *ortho* position at the C-5 position demonstrated moderate or low antibacterial activity against Gram-positive bacteria (MIC 125--500 mg/L). Compound **5c**, demonstrated the highest activity within this group of compounds.

Opposite effect was observed in the case of the 3-α-carboxy-ethyl-5-benzylidene rhodanine derivatives ([@b0110]). In the case of 5-benzylidene derivatives having a nitro group in meta and *para* positions, we did not observe significant antibacterial activity.

The activity of the derivatives having the cinnamylidene substituent with NO~2~ group at the C-5 position was significantly higher than that of the benzylidene derivatives. We observed that compounds having the NO~2~ group in the *para*-position were more active in hindering bacterial growth than those which had nitro group in the *ortho*- position.

Only compound **11a** demonstrated moderate antibacterial activity against Gram-positive bacteria of the tested derivatives with a chlorine atom at the C-5 position substituent. However, none of Gram-negative bacteria strains was susceptible to its activity. Ravi and Sundaram observed that this compound inhibited the growth of *E. coli*, but at very high concentrations exceeding 320 µg/ml ([@b0105]).

Derivatives having a methoxy groups in the substituent at the C-5 position demonstrated no activity against bacteria regardless of the ---OCH~3~ group location in the aromatic ring. We expected that this type of derivatives, due to the presence of an ether bond, would demonstrate activity against Gram-positive bacteria, similarly to the compounds obtained by Miao, ([@b0065]) namely rhodanine-3-acetic acid derivatives having a ((6-benzyloxy)naphthalen-2-yl)methylene moiety at the C-5 position. The derivatives tested by them showed a higher antibacterial activity than those tested by our team, probably due to the larger size of the hydrophobic groups used.

3.3. Lipophilicity {#s0060}
------------------

Transport of chemical compounds, that are potential medicine drugs, through lipids membranes is directly connected to their physical and chemical properties. One of the most important parameters that have significant importance for their biological properties is lipophilicity ([@b0080], [@b0030]).

For all investigated by us compounds we have determined the MIC value and log k~w~ that are important descriptors of lipophilicity.

During our research, we took under consideration only the MIC value determined for Gram-positive bacteria, because investigated compounds did not manifest any activity against Gram-negative bacteria and yeast. Graph of antibacterial activity (log 1/MIC) vs. lipophilicity (log *k~w~*) allowed to connect the structures of investigated compounds with their biological activity and lipophilicity ([Fig. 2](#f0010){ref-type="fig"})**.**Fig. 2Dependence of log 1/MIC on log *k~w~* for all investigated compounds.

The figure illustrates three groups of investigated compounds showing similar type of dependence between biological activity and lipophilicity. These three groups of compounds are detailed in [Fig. 3](#f0015){ref-type="fig"}.Fig. 3Three groups of compounds exhibiting a similar type of dependence of biological activity on lipophilicity.

The first group contains compounds **6a, 7a, 14b** and **15b**. In this group, much higher activity was shown by derivatives that contain 4′-N,N-diethylaminocinnamylidene substituent than these containing 4′-N,N-dimethylaminobenzylidene substituent at C-5 position. In pairs **6a**, **7a** and **14b**, **15b,** higher activity and lipophilicity was shown by rhodanine-3-propionic acid derivatives than by rhodanine-3-acetic acid derivatives.

The second group includes following derivatives: **6b, 7b, 14a** and **15a.** In this group, activity and lipophilicity of rhodanine-3-acetic acid derivatives was significantly lower than activity of rhodanine-3-propionic acid derivatives. A factor that caused that derivatives containing in their structure an amino substituent did not form one group with similar properties, was probably different distribution of electron density within molecules ([@b0130], [@b0010]).

The third group includes four derivatives containing nitro group at the *para* position and two derivatives containing nitro group at the *ortho* position. They are following compounds: **4c, 5c, 12b, 13b** and **4a, 5a.** In this group, the highest activity and the highest lipophilicity was shown by compound **13b,** while the lowest activity and the lowest lipophilicity was shown by **4c**. Compounds **4a** and **5a**, that contain 2′-nitrobenzylidene substituent at position C-5, showed similar activity as their isomers containing 4′-nitrobenzylidene substituent at the position C-5. Derivatives **12a, 13a,** as well as **4b** and **5b** showed lower biological activity than other compounds containing nitro group at position C-5.

Other investigated compounds did not show clear dependence between their structure and biological activity or lipophilicity.

3.4. X-ray crystallographic studies of **15b** and **17** {#s0065}
---------------------------------------------------------

The unit cell consists of two **15b** molecules related by the inversion center. The molecular geometry in the crystal structure of **15b** with the atom numbering scheme is shown in [Fig. 4](#f0020){ref-type="fig"}.Fig. 4Molecular structure of **15b** with the atom numbering scheme.

The molecule has two double bonds C5C6 and C7C8 and can form four geometric isomers (Z, Z; E, E; Z, E or E, Z). In the crystal structure of **15b** the 5Z, 7E isomer is observed. This isomer also occurred in another crystal structure determined earlier, containing rhodanine and aromatic rings connected together with the same chain ([@b0135]). In the Cambridge Structural Database (CSD, Version 5.39) ([@b0015]) there are no other crystal structures with the same chain connecting rhodanine and aromatic rings. The majority of rhodanine derivatives with determined crystal structures, deposited in the CSD, have additional methyl group at the C7 atom and form the same isomer.

The rhodanine and aromatic rings are almost coplanar, the interplanar angle is 10.9(1)°. Two ethyl groups at the N2 atom are directed oppositely to the phenyl ring plane, similar as in other crystal structures of 5-benzylidenerhodanine derivative containing N,N-diethyl substituent at benzylidene moiety ([@b0095], [@b0140]). The angle between the plane of thiazolidine ring (S1, C2, N3, C4, C5) and the plane of carboxyl group (C17, O2, O3) is 88.7(2)°. This value is a little higher as in other 3-carboxyethylrhodanine derivatives, 81.2° and 82.0° ([@b0135], [@b0095]) and it differs from the values 40.3° and 55.8° observed in the crystal structure of another 3-carboxyethylrhodanine derivative ([@b0140]) and 3-carboxyethylrhodanine ([@b0125]).

The crystal packing is determined by O---H⋯O intermolecular interactions, created by carboxylic groups of two molecules related by inversion center ([Fig. 5](#f0025){ref-type="fig"}). These interactions lead to the formation of dimers, that are joined to each other by C---H⋯O and C---H⋯S contacts. Parameters of mentioned interactions are listed in [Table 5](#t0025){ref-type="table"}. In addition, the layers are observed in the crystal structure. Similar arrangement of 3-carboxyethylrhodanine derivatives was noticed in other crystal structures ([@b0135], [@b0095]).Fig. 5Partial packing view of **15b**. Dashed lines indicate hydrogen bonds.Table 5Parameters of intermolecular interactions of **15b** and **17.**CompdD-H⋯AH⋯A (Å)D⋯A (Å)D-H-A (°)Symmetry codes**15b**O3-H3⋯O21.82(3)2.642(2)177(3)−x − 1, −y + 1, −z + 2C6-H6⋯O12.433.282(2)149−x, −y, −z + 2C8-H8⋯O12.683.494(2)144−x, −y, −z + 2C10-H10⋯S22.843.596(2)138−x, −y, −z + 1C21-H21C⋯O12.532.642177(3)−x + 1, −y, −z + 2  **17**O3-H3⋯O41.87(3)2.647(2)176(4)O3-H3⋯S32.77(3)3.478(2)152(3)C6-H6⋯O12.523.399(2)154−x + 1/2, −y − 3/2, −zC8-H8⋯O12.483.380(2)158−x + 1/2, −y − 3/2, −zC7-H7⋯S22.913.853(2)173−x + 1/2, −y, −z + 1/2C10-H10⋯S23.013.963(2)176−x + 1/2, −y, −z + 1/2C18-H18A⋯O42.643.559(4)156−x, −y, −zC18-H18B⋯CL12.923.738(3)142x − 1/2, −y − 3/2, z − 1/2C18-H18C⋯CL12.973.630(3)125x − 1/2, −y − 1/2, z − 1/2C19-H19B⋯O22.613.373(4)135C19-H19C⋯O42.523.262(4)132x, y + 1, z

The asymmetric unit consists of one molecule of **17** and one molecule of dimethyl sulfoxide from the solvent ([Fig. 6](#f0030){ref-type="fig"}).Fig. 6Molecular structure of **17** with the atom numbering scheme.

Similar as in **15b** the 5Z, 7E isomer in the crystal structure is observed. The fragment of molecule containing rhodanine and aromatic ring, connected by prop-2-enylidene chain, is more planar than in **15b**. The interplanar angle between the planes of both rings is 3.6(1)°. Thus the flat fragment was also observed in another crystal structure containing phenyl and rhodanine rings joined together by prop-2-enylidene chain ([@b0135]). The angle between the rhodanine ring and carboxyl group is close to the value of this angle presented above, which is equal to 86.5(1)°.

In the crystal lattice, the carboxylic groups are engaged in the hydrogen bonds with DMSO molecules ([Fig. 7](#f0035){ref-type="fig"}). Additionally, the C---H⋯O, C---H⋯S and C---H⋯Cl intermolecular interactions were observed. The parameters of these interactions are listed in [Table 5](#t0025){ref-type="table"}.Fig. 7Partial packing view of **17**. Dashed lines indicate hydrogen bonds.

4. Conclusions {#s0070}
==============

Among all compounds investigated by us, the highest activity characterized derivatives of rhodanine-3-acetic and rhodanine-3-propionic acids having at the C-5 position cinnamylidene substituent containing a dialkylamino or nitro group in the *para* position. The size of alkyl groups in the dialkylamine moiety significantly affects the antimicrobial activity.

Derivatives containing a diethylamino group have higher activity than those containing a dimethylamino group. The presence of chlorine atoms or methoxy groups in the arylidene moiety does not increase the antibacterial activity of the tested compounds. The obtained results will allow to plan further research in order to obtain compounds with even higher antibacterial activity.

The crystal structure of more active compound **15b** shows the less planarity of 5-cinnamylidenerhodanine fragment in comparison to **17** and the involvement of N,N-diethyl substituent as donor in C---H⋯O intermolecular contacts.

Appendix A. Supplementary material {#s0090}
==================================

The following are the Supplementary data to this article:Supplementary data 1
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